Vifor Pharma, Angion sign licensing agreement for ANG-3777 commercialization

Vifor Pharma and Angion announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function, or DGF, and cardiac surgery-associated acute kidney injury, or CSA-AKI. ANG-3777 was engineered to mimic the biological activity of HGF, activating pathways in the body's natural organ repair process following an acute organ injury. Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications. Angion will receive up to $80M which includes a $30M upfront payment, a $30M equity investment and $20M in clinical study milestone payments. Additionally Angion is eligible to receive up to $260M in market access related milestones upon approval in U.S. and EU, further payments in the form of sales milestones, and tiered royalties on global net sales up to 40% at the high end of the royalty range. Angion will be responsible for conducting the ongoing nephrology-focused clinical development programs. Angion and Vifor Pharma will share responsibilities for regulatory filings in the licensed territories and Vifor Pharma will be responsible for all commercialization activities related to nephrology indications in all licensed territories.